Tech Company Financing Transactions
Psyadon Pharmaceuticals Funding Round
Psyadon Pharmaceuticals, operating out of Germantown, secured $2 million from New Enterprise Associates.
Transaction Overview
Company Name
Announced On
12/31/2010
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Undisclosed
Investors
New Enterprise Associates (James Barrett)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20451 Seneca Meadows Parkway
Germantown, MD 20876
USA
Germantown, MD 20876
USA
Phone
Website
Email Address
Overview
Psyadon Pharmaceuticals is dedicated to the discovery and development of new treatments for the serious psychiatric and neurological diseases. Ecopipam, our first development candidate, selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Chipkin
Browse more venture capital transactions:
Prev: 12/31/2010: Aveso Displays venture capital transaction
Next: 12/31/2010: Ingrain venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs